{
    "nct_id": "NCT04295863",
    "official_title": "A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers",
    "inclusion_criteria": "* Patients with locally advandced or metastatic cancer whose physician has determined they are candidates for treatment with nivolumab or pembrolizumab\n* 18 years old or older\n* Measurable disease per RECIST criteria\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy.\n* Patients whose treatment plan is to receive ipilimumab or other anti-CTLA4 monoclonal antibody in combination with either nivolumab or pembrolizumab.\n\n  * Ipilimumab and nivolumab combination are not eligible for this trial.\n  * (Note: Patients whose planned treatment is the combination of anti-PD-1 and tyrosine kinase inhibitor such as pembrolizumab-axitinib or the combination of traditional cytotoxic chemotherapy and anti-PD-1 are eligible)",
    "miscellaneous_criteria": ""
}